

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-12. (canceled).

13. (previously presented): A method for treatment of cancer, wherein a pharmaceutically effective amount of completely human anti-PD-1 antibody is parenterally administered to a subject with cancer in which PD-L1 or PD-L2 is over-expressed, postoperatively.

14. (original) The method for treatment of cancer according to claim 13, which suppresses cancer metastasis.

15 - 33 (canceled).

34. (previously presented): A method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells, which comprises parenterally administering a pharmaceutically effective amount of a completely human anti-PD-1 antibody to a subject with cancer in which PD-L1 or PD-L2 is over-expressed.

35. (previously presented): The method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells according to claim 34, which suppresses cancer metastasis.

36. (previously presented): The method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells according to claim 34, wherein the effective dose of the completely human anti-PD-1 antibody is administered postoperatively.